이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BioArctic 관리

관리 기준 확인 2/4

BioArctic's CEO는 Gunilla Osswald, Jan2014 에 임명되었습니다 의 임기는 10.42 년입니다. 총 연간 보상은 SEK 22.38M, 19.8% 로 구성됩니다. 19.8% 급여 및 80.2% 보너스(회사 주식 및 옵션 포함). 는 SEK 20.19M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 20.19M. 경영진과 이사회의 평균 재임 기간은 각각 5.4 년과 6.8 년입니다.

주요 정보

Gunilla Osswald

최고 경영자

SEK 22.4m

총 보상

CEO 급여 비율	19.8%
CEO 임기	10.7yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	5.7yrs
이사회 평균 재임 기간	6.7yrs

최근 관리 업데이트

Recent updates

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Sep 01

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Aug 15

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

Apr 13

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 19

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Feb 03

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Dec 23

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Nov 12

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Jul 21

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Jul 15

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Jul 07

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

May 06

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Mar 13

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Nov 30

BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate

Sep 15

BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business

Aug 23

CEO 보상 분석

Gunilla Osswald 의 보수는 BioArctic 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-SEK 88m
Mar 31 2024	n/a	n/a	-SEK 122m
Dec 31 2023	SEK 22m	SEK 4m	SEK 229m
Sep 30 2023	n/a	n/a	SEK 259m
Jun 30 2023	n/a	n/a	SEK 270m
Mar 31 2023	n/a	n/a	SEK 327m
Dec 31 2022	SEK 9m	SEK 5m	-SEK 11m
Sep 30 2022	n/a	n/a	SEK 28m
Jun 30 2022	n/a	n/a	-SEK 147m
Mar 31 2022	n/a	n/a	-SEK 135m
Dec 31 2021	SEK 5m	SEK 3m	-SEK 120m
Sep 30 2021	n/a	n/a	-SEK 114m
Jun 30 2021	n/a	n/a	-SEK 97m
Mar 31 2021	n/a	n/a	-SEK 101m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 69m
Sep 30 2020	n/a	n/a	-SEK 72m
Jun 30 2020	n/a	n/a	-SEK 60m
Mar 31 2020	n/a	n/a	SEK 78m
Dec 31 2019	SEK 7m	SEK 3m	SEK 88m
Sep 30 2019	n/a	n/a	SEK 441m
Jun 30 2019	n/a	n/a	SEK 475m
Mar 31 2019	n/a	n/a	SEK 380m
Dec 31 2018	SEK 5m	SEK 3m	SEK 382m
Sep 30 2018	n/a	n/a	SEK 58m
Jun 30 2018	n/a	n/a	SEK 32m
Mar 31 2018	n/a	n/a	SEK 29m
Dec 31 2017	SEK 3m	SEK 2m	SEK 15m

보상 대 시장: Gunilla 의 총 보상 ($USD 2.14M )은 Swedish 시장( $USD 776.13K ).

보상과 수익: 회사가 수익성이 없는 동안 Gunilla 의 보상이 증가했습니다.

CEO

Gunilla Osswald (63 yo)

10.7yrs

테뉴어

SEK 22,378,000

보상

Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...

리더십 팀

이름	위치	테뉴어	보상	소유권
Gunilla Osswald	President & CEO	10.7yrs	SEK 22.38m	0.11% SEK 15.1m
Pär Gellerfors	Co-Founder	21.7yrs	SEK 390.00k	데이터 없음
Lars Lannfelt	Co-Founder	21.7yrs	SEK 2.54m	33.42% SEK 4.7b
Anders Martin-Lof	Chief Financial Officer	1.3yrs	데이터 없음	데이터 없음
Johanna Fälting	Chief Research Officer & Head of Research	no data	데이터 없음	0.051% SEK 7.2m
Christer Möller	VP of Pre-Clinical Development & Chief Scientific Officer	18.7yrs	데이터 없음	0.063% SEK 8.9m
Oskar Bosson	VP and Head of IR & Communication	4.3yrs	데이터 없음	0.016% SEK 2.3m
Leif Gallo	General Counsel and Head of Legal & IP	no data	데이터 없음	데이터 없음
Harald Borgeke	Head of Public Affairs	2.4yrs	데이터 없음	데이터 없음
Frida Lekander	Head of Marketing	2.6yrs	데이터 없음	데이터 없음
Gunilla Andersson	Vice President of Human Resources	5.7yrs	데이터 없음	데이터 없음
Mikael Moge	VP & Head of CMC	no data	데이터 없음	0.011% SEK 1.5m

5.7yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: BIOA B 의 관리팀은 노련하고 경험 (평균 재직 기간 5.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Pär Gellerfors	Co-Founder	21.7yrs	SEK 390.00k	데이터 없음
Lars Lannfelt	Co-Founder	21.7yrs	SEK 2.54m	33.42% SEK 4.7b
Eugen Steiner	Independent Chairman	7yrs	SEK 621.00k	0.10% SEK 14.2m
Hans Wigzell	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Konrad Beyreuther	Member of the Scientific Board	no data	데이터 없음	데이터 없음
Marie Edström	Independent Director	1.3yrs	SEK 187.00k	데이터 없음
Mikael Smedeby	Independent Director	6.3yrs	SEK 316.00k	0.032% SEK 4.5m
Charlotta Ljungqvist	Independent Director	3.3yrs	SEK 318.00k	0.0036% SEK 506.3k
Martin Ingelsson	Member of Scientific Board	no data	데이터 없음	데이터 없음
Staffan Pauli	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ken Marek	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kaj Blennow	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.7yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: BIOA B 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

BioArctic 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Vice President of Human Resources exercised options and sold kr454k worth of stock

Insufficient new directors

Insider recently sold kr710k worth of stock

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

Independent Chairman recently bought kr1.1m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

Recent updates

Vice President of Human Resources exercised options and sold kr454k worth of stock

BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 9.3% to kr291

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024

Price target decreased by 8.6% to kr336

New major risk - Share price stability

Insufficient new directors

Insider recently sold kr710k worth of stock

BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea

First quarter 2024 earnings: Revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Consensus EPS estimates increase by 112%

Vice President of Human Resources exercised options to buy kr1.2m worth of stock.

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 15%

News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 14%

With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research exercised options to buy kr1.2m worth of stock.

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Consensus revenue estimates increase by 13%

BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be

Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)

Consensus revenue estimates increase by 12%

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Now 21% undervalued

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth

Independent Director recently sold kr3.3m worth of stock

Price target increased by 12% to kr400

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Consensus EPS estimates fall by 60%

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

Consensus forecasts updated

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher

Consensus forecasts updated

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released: EPS: kr1.55 (vs kr0.43 loss in 3Q 2021)

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn